Please Wait
Applying Filters...
menu
    • menu
    European CDMO and Gx manufacturer with 75 years of experience in delivering premium APIs to pharmaceutical partners worldwide.

    Virtual Booth

    Contact Supplier

    Minakem delivers API, HPAPI, steroids & CDMO services for generics with FDA/GMP certification, regulatory know-how & proven success.

    Virtual Booth

    Contact Supplier

    USP reference standards; highly characterized specimens of drug substances, impurities, excipients, degradation products & more.

    Virtual Booth

    Contact Supplier

    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients, & custom-made solutions to our customers.

    Virtual Booth

    Contact Supplier

    Guizhou Utide Biotechnology Co., Ltd. - Specialized GMP manufacturing for next-generation GLP-1 peptide APIs.

    Virtual Booth

    Contact Supplier

    Menu

    Rusfertide

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Protagonist Prefers $400M From Takeda Over Rusfertide US Profits
    Protagonist Prefers $400M From Takeda Over Rusfertide US Profits

    26 Feb 2026

    // FIERCE BIOTECH

    https://www.fiercebiotech.com/biotech/protagonist-plans-pocket-400m-takeda-rather-split-us-rusfertide-profits

    FIERCE BIOTECH
    26 Feb 2026
    Share Share
    Protagonist Reveals 2025 Financials And Corporate Update
    Protagonist Reveals 2025 Financials And Corporate Update

    25 Feb 2026

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2026-02-25/protagonist-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-corporate-updat

    PHARMIWEB
    25 Feb 2026
    Share Share
    Protagonist's $400M JPM26 Decision Is Total No-Brainer
    Protagonist's $400M JPM26 Decision Is Total No-Brainer

    16 Jan 2026

    // BIOSPACE

    https://www.biospace.com/business/jpm26-protagonist-has-a-400m-decision-to-make-its-a-no-brainer

    BIOSPACE
    16 Jan 2026
    Share Share
    Takeda, Protagonist Submit Rusfertide (NDA) For Polycythemia Vera
    Takeda, Protagonist Submit Rusfertide (NDA) For Polycythemia Vera

    05 Jan 2026

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20260101831438/en/Takeda-and-Protagonist-Announce-Submission-of-New-Drug-Application-NDA-for-Rusfertide-for-Treatment-of-Polycythemia-Vera-PV

    BUSINESSWIRE
    05 Jan 2026
    Share Share
    Protagonist, Takeda Present Rusfertide PV Data at ASH 2025
    Protagonist, Takeda Present Rusfertide PV Data at ASH 2025

    06 Dec 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20251205962286/en/Protagonist-and-Takeda-Present-Longer-Term-Data-at-ASH-2025-Showing-Rusfertide-Delivers-Durable-Response-and-Hematocrit-Control-in-Polycythemia-Vera

    BUSINESSWIRE
    06 Dec 2025
    Share Share
    Protagonist Reveals Q3 2025 Financials & Corporate Update
    Protagonist Reveals Q3 2025 Financials & Corporate Update

    06 Nov 2025

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2025-11-06/protagonist-reports-third-quarter-2025-financial-results-and-provides-corporate-update

    PHARMIWEB
    06 Nov 2025
    Share Share
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.